Chinese Journal of Clinical Hepatology最新文献

筛选
英文 中文
IDDF2021-ABS-0112 Safety of continuing anticoagulation during endoscopic variceal ligation in cirrhosis patients: a systematic review and meta-analysis 肝硬化患者内镜下静脉曲张结扎期间持续抗凝治疗的安全性:一项系统回顾和荟萃分析
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.91
W. Tay, Gerald Low Jun Teck, J. Loo, Le Shaun Ang, Y. Wong
{"title":"IDDF2021-ABS-0112 Safety of continuing anticoagulation during endoscopic variceal ligation in cirrhosis patients: a systematic review and meta-analysis","authors":"W. Tay, Gerald Low Jun Teck, J. Loo, Le Shaun Ang, Y. Wong","doi":"10.1136/gutjnl-2021-iddf.91","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.91","url":null,"abstract":"Background Endoscopic variceal ligation (EVL) is a common procedure for primary and secondary prevention of variceal bleeding in cirrhosis patients. As portal vein thrombosis is associated with a higher risk of variceal bleeding and decompensation in cirrhosis patients, anticoagulation may be considered in these patients. However, it is uncertain if continuing anticoagulation during EVL may significantly increase the risk of bleeding. To address this gap, we performed a systematic review and meta-analysis to evaluate the safety of continuing anticoagulation during EVL. The primary outcome was the bleeding risk following EVL. Secondary outcomes were mortality following EVL and length of stay (LOS). Methods We performed a systematic search of 4 electronic databases (PubMed/MEDLINE, EMBASE, Cochrane library, and ClinicalTrial.gov) up to May 21, 2021 using both free text and MeSH terms. We included all studies that reported the 4-week rebleeding rate in cirrhosis patients during EVL, regardless of study design, language, publication types or status. The pooled relative risk (RR), mean difference (MD) and 95% confidence interval (95%CI) of study outcomes were estimated using Review Manager in a random-effect model. Results A total of six studies (5,102 subjects, 1,028 received anticoagulation) fulfilled our inclusion criteria. The mean (standard deviation) MELD and Child-Pugh score were 18 (5.5) and 7 (1.6), respectively. Follow-up duration ranged from 6 to 196 weeks. The overall pooled risk of bleeding and mortality was 8.2% (95%CI: 6.6%-10.0%) and 8.6% (95%CI: 4.2%-15.3%), respectively. Mean number of bands deployed per session was similar between the anticoagulation and control group. Continuation of anticoagulants during EVL was not associated with a higher pooled risk of bleeding (RR: 0.90, 95%CI: 0.71-1.15, I2 =0%) and mortality (RR: 1.16, 95%CI: 0.22-6.19) following EVL. However, continuing anticoagulation was associated with a shorter LOS (3.9 days, 95%CI: -7.35 to -0.48 days, I2 =0%). All studies had a low risk of bias except for one. Conclusions In cirrhosis patients undergoing EVL, continuing anticoagulation was safe without a significant increase in bleeding and mortality.","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84837802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0116 Surgical treatment for non-colorectal non-neuroendocrine liver metastases: a systematic review and meta-analysis 非结直肠非神经内分泌肝转移的手术治疗:系统回顾和荟萃分析
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.92
K. Ng, N. Cheng, H. Lok, C. Chong, J. Wong, Kit-fai Lee
{"title":"IDDF2021-ABS-0116 Surgical treatment for non-colorectal non-neuroendocrine liver metastases: a systematic review and meta-analysis","authors":"K. Ng, N. Cheng, H. Lok, C. Chong, J. Wong, Kit-fai Lee","doi":"10.1136/gutjnl-2021-iddf.92","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.92","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72863543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0190 Improving hepatitis B vaccination and response rate in liver transplant recipients 改善肝移植受者乙肝疫苗接种和应答率
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-IDDF.102
Shirley Huey Shin, Bong, Elaine Ah Gi, Lo, Eunice Xiang Xuan, Tan, Guan-Huei, Lee
{"title":"IDDF2021-ABS-0190 Improving hepatitis B vaccination and response rate in liver transplant recipients","authors":"Shirley Huey Shin, Bong, Elaine Ah Gi, Lo, Eunice Xiang Xuan, Tan, Guan-Huei, Lee","doi":"10.1136/gutjnl-2021-IDDF.102","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-IDDF.102","url":null,"abstract":"IDDF2021-ABS-0190 Figure 1ConclusionsThe development of a standardised workflow can lead to improvement in anti-HBs testing and compliance to vaccination post-LT. These findings may be useful for other patients who are on long-term immunosuppression. Continual efforts from the multidisciplinary team are required to ensure the sustainability of effect.","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88070043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD) 中度或重度肾功能损害或终末期肾病(ESRD)的病毒抑制型慢性乙型肝炎(CHB)患者从富马酸替诺福韦二氧丙酯(TDF)和/或其他口服抗病毒药物(OAVS)切换到替诺福韦α胺(TAF)
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.80
H. Janssen, P. Lampertico, Chien-Hung Chen, J. Heo, C. Fournier, S. Ahn, Tak Yin Owen Tsang, C. Coffin, Yi-Hsang Huang, G. Marchesini, A. Hui, M. Elkhashab, Sayed Jafri, Carol Yee Kwan Chan, Susanna K. Tan, Yang Zhao, V. Suri, J. Flaherty, A. Gaggar, D. Brainard, W. Chuang, K. Agarwal, E. Gane, Y. Lim
{"title":"IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD)","authors":"H. Janssen, P. Lampertico, Chien-Hung Chen, J. Heo, C. Fournier, S. Ahn, Tak Yin Owen Tsang, C. Coffin, Yi-Hsang Huang, G. Marchesini, A. Hui, M. Elkhashab, Sayed Jafri, Carol Yee Kwan Chan, Susanna K. Tan, Yang Zhao, V. Suri, J. Flaherty, A. Gaggar, D. Brainard, W. Chuang, K. Agarwal, E. Gane, Y. Lim","doi":"10.1136/gutjnl-2021-iddf.80","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.80","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88593064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0030 4D ultrasonography for therapeutic radiofrequency ablation for hepatocellular carcinoma-included enhanced-ultrasonography IDDF2021-ABS-0030用于肝细胞癌射频消融治疗的4D超声包括增强超声
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.65
N. Hotta
{"title":"IDDF2021-ABS-0030 4D ultrasonography for therapeutic radiofrequency ablation for hepatocellular carcinoma-included enhanced-ultrasonography","authors":"N. Hotta","doi":"10.1136/gutjnl-2021-iddf.65","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.65","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89926856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0083 Assessment pre- and post-treatment quality of life by eortc QLQ-30 questionnaire in patients with hepatocellular carcinoma at hanoi medical university, Vietnam iddf2021 - ab -0083越南河内医科大学肝细胞癌患者治疗前后生活质量评价
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.83
Thuy Trang Ha, M. Pham, Ngoc Anh Trang
{"title":"IDDF2021-ABS-0083 Assessment pre- and post-treatment quality of life by eortc QLQ-30 questionnaire in patients with hepatocellular carcinoma at hanoi medical university, Vietnam","authors":"Thuy Trang Ha, M. Pham, Ngoc Anh Trang","doi":"10.1136/gutjnl-2021-iddf.83","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.83","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76990486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0080 96-week efficacy and safety of tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switch vs. continued TDF treatment among virologically-suppressed hepatitis B patients of asian ethnicity 在病毒学抑制的亚洲乙肝患者中,富马酸替诺福韦二氧吡酯(TDF)转替诺福韦α胺(TAF)与继续TDF治疗的96周疗效和安全性比较
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.82
S. Ahn, J. Kao, P. Lampertico, A. Ramji, S. Fung, W. Chuang, Y. Kim, Chi-yi Chen, E. Tam, H. Bae, Xiaoli Ma, June-Sung Lee, Carol Yee Kwan Chan, L. Yee, S. Sethi, J. Flaherty, Yang Zhao, A. Gaggar, H. Hann, Y. Lim, H. Chan
{"title":"IDDF2021-ABS-0080 96-week efficacy and safety of tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switch vs. continued TDF treatment among virologically-suppressed hepatitis B patients of asian ethnicity","authors":"S. Ahn, J. Kao, P. Lampertico, A. Ramji, S. Fung, W. Chuang, Y. Kim, Chi-yi Chen, E. Tam, H. Bae, Xiaoli Ma, June-Sung Lee, Carol Yee Kwan Chan, L. Yee, S. Sethi, J. Flaherty, Yang Zhao, A. Gaggar, H. Hann, Y. Lim, H. Chan","doi":"10.1136/gutjnl-2021-iddf.82","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.82","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86596435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0050 Validation of platelet-albumin- bilirubin (PALBI) score for predicting overall survival of hepatocellular carcinoma 血小板-白蛋白-胆红素(PALBI)评分预测肝细胞癌总生存期的验证
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.72
M. Pham, N. Tran
{"title":"IDDF2021-ABS-0050 Validation of platelet-albumin- bilirubin (PALBI) score for predicting overall survival of hepatocellular carcinoma","authors":"M. Pham, N. Tran","doi":"10.1136/gutjnl-2021-iddf.72","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.72","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79710675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0172 Efficacy and safety of direct oral anticoagulants versus vitamin K antagonists for portal vein thrombosis in cirrhosis: a systematic review and meta-analysis 直接口服抗凝剂与维生素K拮抗剂治疗肝硬化门静脉血栓的疗效和安全性:一项系统综述和荟萃分析
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.100
Sherilyn Zi Hui Liew, J. H. Koh, Gin-Kee Ng, H. Liu, Y. Tam, A. Gottardi, Y. Wong
{"title":"IDDF2021-ABS-0172 Efficacy and safety of direct oral anticoagulants versus vitamin K antagonists for portal vein thrombosis in cirrhosis: a systematic review and meta-analysis","authors":"Sherilyn Zi Hui Liew, J. H. Koh, Gin-Kee Ng, H. Liu, Y. Tam, A. Gottardi, Y. Wong","doi":"10.1136/gutjnl-2021-iddf.100","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.100","url":null,"abstract":"","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88941042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IDDF2021-ABS-0008 Is fatty liver associated with depression? A meta-analysis and systematic review on prevalence, risk factors and outcomes of depression and non-alcoholic fatty liver disease 脂肪肝与抑郁症相关吗?抑郁症和非酒精性脂肪肝患病率、危险因素及预后的meta分析和系统综述
Chinese Journal of Clinical Hepatology Pub Date : 2021-09-01 DOI: 10.1136/gutjnl-2021-iddf.61
C. Ng, J. Xiao, Lincoln Kai En Lim, D. Tan, W. Lim, Cyrus S. H. Ho, E. Tan, A. Sanyal, M. Muthiah
{"title":"IDDF2021-ABS-0008 Is fatty liver associated with depression? A meta-analysis and systematic review on prevalence, risk factors and outcomes of depression and non-alcoholic fatty liver disease","authors":"C. Ng, J. Xiao, Lincoln Kai En Lim, D. Tan, W. Lim, Cyrus S. H. Ho, E. Tan, A. Sanyal, M. Muthiah","doi":"10.1136/gutjnl-2021-iddf.61","DOIUrl":"https://doi.org/10.1136/gutjnl-2021-iddf.61","url":null,"abstract":"IDDF2021-ABS-0008 Figure 1 Abstracts A64 Gut 2021;70(Suppl 2):A1–A150 on S etem er 1, 2021 by gest. P rocted by coright. http/gut.bm jcom / G t: frst pulished as 10.113utjnl-2021-ID D F 61 on 2 S etem er 221. D ow nladed fom aimed to assess the association between depression and NAFLD. Methods A search of the literature was conducted on Medline and Embase databases to identify articles relating to NAFLD and depression. A meta-analysis of proportions was conducted using the generalized linear mix model with Copper Pearson intervals to stabilize the variance. Risk factors were analyzed using the odds ratios and mean difference for dichotomous and continuous variables respectively. To compare between the rate of depression between NAFLD (non-alcholic fatty liver disease) and NASH (nonalcoholic steatohepatitis), the relative risks (RR) were calculated using the depression in NASH vs NAFLD as the ratio of the pooled proportion and confidence interval by the Katz-logarithmic method. Results Of 1315 unique abstracts identified, 10 articles involving 2,041,752 NAFLD patients were included (IDDF2021ABS-0008 Figure 1. Overall Prevalence of Depression in NAFLD). In a pooled analysis of studies, there was a significant relationship between the diagnosis of depression and NAFLD (OR: 1.29, CI: 1.02 1.64, p=0.03). The overall pooled prevalence of depression in NAFLD was14.39% (CI: 8.89% 22.45%). The prevalence of depression in nonalcoholic steatohepatitis (NASH) is 40.68% (CI: 25.11% 58.37%), significantly higher than that in NAFLD at 14.39% (CI: 8.89% 22.45%). Compared to NAFLD, patients with NASH had a significantly higher risk of depression (RR: 2.83, CI: 2.41 3.32, p <0.001). Diabetes, BMI, female sex, history of smoking and history of lung disease were significant risk factors associated with depression in NAFLD patients and depression in NAFLD patients was an independent predictor of all-cause 1-year mortality. Conclusions To our knowledge, this is the first meta-analysis to describe a positive association between NAFLD and depression with an increasing rate of depression in NASH compared to NAFLD (IDDF2021-ABS-0008 Figure 2. Graphical Depiction of the Overall Results). However, more studies are required to observe the impact of depression and clinical outcomes in NAFLD. IDDF2021-ABS-0010 A META-ANALYSIS AND METAREGRESSION BETWEEN LIVER RESECTION AND LIVER TRANSPLANT WITHIN MILIAN CRITERIA Cheng Han Ng*, Jin Hean Koh, Yuki Ong, Wen Hui Lim, Darren Jun Hao Tan, Mark Muthiah, Nicholas Syn, Brian Goh, Daniel Huang. Yong Loo Lin School of Medicine, Singapore; Singapore General Hospital, Singapore 10.1136/gutjnl-2021-IDDF.62 Background Hepatocellular carcinoma (HCC) is the dominant form of primary liver cancer and a leading cause of cancer globally. Liver transplantation (LT) confers excellent long-term survival outcomes, but its effectiveness is hampered by the dire shortage of liver allografts. Liver resection (LR) is a promising alternative due to favorable","PeriodicalId":9921,"journal":{"name":"Chinese Journal of Clinical Hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89698910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信